Prediction of Postoperative Pulmonary Complications in a Population-based Surgical Cohort

Jaume Canet, M.D., Ph.D.,* Lluís Gallart, M.D., Ph.D.,† Carmen Gomar, M.D., Ph.D.,‡ Guillem Paluzie, M.D.,§ Jordi Vallès, M.D.,† Jordi Castillo, M.D., Ph.D.,† Sergi Sabaté, M.D., Ph.D.,| Valentín Mazo, M.D.,# Zahara Briones, M.Math.,** Joaquín Sanchis, M.D., Ph.D.††; on behalf of the ARISCAT Group‡‡

ABSTRACT

Background: Current knowledge of the risk for postoperative pulmonary complications (PPCs) rests on studies that narrowly selected patients and procedures. Hypothesizing that PPC occurrence could be predicted from a reduced set of perioperative variables, we aimed to develop a predictive index for a broad surgical population.

Methods: Patients undergoing surgical procedures given general, neuraxial, or regional anesthesia in 59 hospitals were randomly selected for this prospective, multicenter study. The main outcome was the development of at least one of the following: respiratory infection, respiratory failure, bronchospasm, atelectasis, pleural effusion, pneumothorax, or aspiration pneumonitis. The cohort was randomly divided into a development subsample to construct a logistic regression model and a validation subsample. A PPC predictive index was constructed.

Results: Of 2,464 patients studied, 252 events were ob-

Received from the Department of Anesthesiology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. Submitted for publication January 22, 2010. Accepted for publication August 25, 2010. Support was provided by Grant 041610-2003 for "Fundació La Marató de TV3 (Televisió de Catalunya)" (Barcelona, Spain). Article partially presented at the 2008 Euroanesthesia Congress, Copenhagen, Denmark, May 31–June 3, 2008.

Address correspondence to Dr. Canet: Department of Anesthesiology, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n, Badalona, Barcelona, Spain. jcanet.germanstrias@gencat.cat. This article may be accessed for personal use at no charge through the Journal Web site, www.anesthesiology.org.

served in 123 (5%). Thirty-day mortality was higher in patients with a PPC (19.5%; 95% [CI], 12.5–26.5%) than in those without a PPC (0.5%; 95% CI, 0.2–0.8%). Regression modeling identified seven independent risk factors: low preoperative arterial oxygen saturation, acute respiratory infection during the previous month, age, preoperative anemia, upper abdominal or intrathoracic surgery, surgical duration of at least 2 h, and emergency surgery. The area under the receiver operating characteristic curve was 90% (95% CI, 85–94%) for the development subsample and 88% (95% CI, 84–93%) for the validation subsample.

Conclusion: The risk index based on seven objective, easily assessed factors has excellent discriminative ability. The index can be used to assess individual risk of PPC and focus further research on measures to improve patient care.

What We Already Know about This Topic

Postoperative pulmonary complications result in major morbidity and mortality, but risk factors for such complications are not described in a large, heterogeneous population.

What This Article Tells Us That Is New

- In a prospective, multicenter study of nearly 2,500 patients, seven factors provided a sensitive and specific prediction of risk for postoperative pulmonary complications.
- Application of these data can stratify patients for risks in both research and clinical practice.

POSTOPERATIVE pulmonary complications (PPCs) account for a substantial proportion of risk related to surgery and anesthesia and are a major cause of postoperative morbidity, mortality, and longer hospital stays.^{1,2} In one

- This article is featured in "This Month in Anesthesiology."Please see this issue of ANESTHESIOLOGY, page 9A.
- Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are available in both the HTML and PDF versions of this article. Links to the digital files are provided in the HTML text of this article on the Journal's Web site (www.anesthesiology.org).

^{*} Chairman, Department of Anesthesiology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain, † Staff Anesthesiologist, Department of Anesthesiology, Hospital del Mar, Institut Municipal d'Investigació Mèdica, Universitat Autònoma de Barcelona, Barcelona, Spain, ‡ Professor, Department of Anesthesiology, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain, § Head of Department of Hospital Medical Records, Corporació de Salut del Maresme i La Selva, Calella, Barcelona, Spain, || Staff Anesthesiologist, Department of Anesthesiology, Fundació Puigvert, Barcelona, Spain, # Staff Anesthesiologist, Department of Anesthesiology Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain, ** Research Fellow, Department of Anesthesiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, †† Professor, Department of Pneumology, Hospital Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, # See appendix.

systematic review of studies of noncardiac surgery, the incidence of PPCs was found to vary from 2 to 19%.³ Identifying patients at risk is an important first step toward improving surgical care, yet research on PPCs to date has been subject to sampling bias. For example, two important studies of risk that analyzed data from the National Veterans Affairs Quality Improvement Program in order to derive indices for predicting risk of pneumonia⁴ and respiratory failure⁵ after noncardiac surgery included mostly male veterans. Systematic review has detected many studies with such bias-introducing limitations as small sample size; narrow selection of patients, comorbidities, and operations; and retrospective or nonblinded outcome assessment. In addition, PPC definitions have differed.² Nonetheless, despite the limitations of such studies, groups still seek to establish risk-mitigating guidelines; the most ambitious attempt to date to marshal current knowledge on this clinical problem is the American College of Physicians guidelines for preventing PPCs in patients undergoing noncardiac surgery.2 In this context, it is clear that it would be very useful to be able to predict the likelihood of PPCs from a reduced perioperative set of variables. Furthermore, an index would be most useful if applicable across a wide range of surgical settings.

We sought to reduce sampling bias by basing our analysis of risk factors on prospectively gathered data from a large population undergoing a broad range of surgical procedures. The population-based sample used was broadly representative of patients from a southern European territory that includes several large cities as well as rural areas. The participating hospitals were also representative of all levels of care. Our goals were to assess the incidence and characteristics of PPCs in this population and to build a scoring system with a reduced number of significant variables that would identify PPC risk in most clinical settings.

Materials and Methods

Desian

We conducted a prospective, multicenter, observational study of a random-sample cohort of patients undergoing nonobstetric in-hospital surgical procedures with general, neuraxial, or regional anesthesia.

Setting

The 59 participating Spanish hospitals (community, intermediate referral, or major tertiary care facilities) included all of the hospitals providing public health services in the autonomous community of Catalonia (7.36 million inhabitants) plus one center in Valencia. Throughout Spain, the entire population has full free access to National Health Service care such as these hospitals provide. The participating centers are known to perform 63% of all in-hospital anesthetic procedures that could provide the patients for the study. Nonparticipant centers in the area were private, and, according to a cross-sectional survey of anesthetic practices in Catalonia completed in 2003, their patients were younger, more fre-

quently women, and had lower American Society of Anesthesiologists physical status and surgical complexity.^{6,7} Recruitment was carried out throughout a full year from January 10, 2006, to January 9, 2007. Follow-up ended in April 2007.

Sampling

To reflect the seasonal, weekly, and daily distribution of the surgical caseload, patients were randomly selected using methods similar to those used in previous surveys. Each center was notified of seven randomly assigned days of the year, one for each day of the week. Two restrictions were imposed: (1) each day of the study period should have a minimum of 1 and a maximum of 2 centers recruiting patients; and (2) for the 20 highest-volume centers, a minimum interval of 15 days should occur between two sampling days.

Inclusion and Exclusion Criteria

On each assigned day, each participating center considered eligible all patients who underwent scheduled or emergency surgery with general, neuraxial, or regional anesthesia. The exclusion criteria were as follows: (1) younger than 18 yr of age; (2) obstetric procedures or any procedure during pregnancy; (3) procedures in which only local or peripheral nerve anesthesia was used; (4) procedures outside the operating room; (5) procedures related to a previous surgical complication; (6) patients who were reoperated on during the 90-day follow-up; (7) organ transplantation; (8) patients with preoperatively intubated trachea; and (9) outpatient procedures, defined as those requiring less than a 1-day stay for a patient alive at discharge.

Ethical Considerations

The ethics committee of each participating center approved the study, and patients or significant others signed informed consent statements for data collection and follow-up telephone contact. If eligible patients were unable to provide consent, relatives or legal representatives were asked to consent. All patients received routine care; no research-related intervention was introduced.

Data Collection

Each local research team consisted of anesthesiologists or was led by anesthesiologists. General and local training sessions were held to instruct the investigators on how to complete the structured questionnaire and how to identify the PPC outcomes recorded in the charts. Questionnaire variables and definitions are shown in Supplemental Digital Content 1, http://links.lww.com/ALN/A646. A short questionnaire on demographic characteristics, smoking status, and type of surgery (scheduled *vs.* emergency) was completed for patients who declined to take part in the study. Responses were uniformly recorded without regard to severity or whether an intervention was a scheduled or an emergency procedure. Local teams used a hot-pursuit approach (*i.e.*, regularly and assiduously checking records to ensure completeness of data

collection in real time and starting from admission). A centralized database and specific applications for remote data recording incorporated quality control algorithms to validate online data entry and identify missing data. A data manager checked entries and asked local teams to confirm completeness of records. An expert on the *International Classification of Diseases, Ninth Revision, Clinical Modification*, coded all diagnoses and procedures at the end of the study. To assess 30- and 90-day mortality, a structured survey was carried out by telephone operators who were blinded to perioperative variables and outcomes. All patients' names were also checked in the National Health Service Death Register for confirmation and date of death. If the date in our records differed from the date in the register, we considered the officially registered date to be valid.

Outcomes

The main outcome, a PPC, was a composite of the in-hospital fatal or nonfatal postoperative events, as defined^{4,9–15} in table 1. Although PPCs were recorded throughout the in-hospital postoperative period, the investigators—usually anesthesiologists—did not modify a center's customary management of patients. Patients with PPCs were identified by consulting medical records in real time, when they were being created, to find events that fulfilled any PPC definition. Any such event occurring during the hospital stay, regardless of postoperative day, was considered a PPC outcome. The secondary outcomes were postoperative length of stay (LOS) and 30-day and 90 day-mortality rates.

Sample Size

In a pilot study, we detected a PPC incidence of 4.1% in 172 patients, similar to previous studies. ^{4,10} According to a cross-sectional survey of anesthetic practices in Catalonia, ⁷ it was expected that the 59 participating centers would be able to recruit at least 2,500 eligible patients in a year and observe 100 patients with at least one PPC.

Statistical Analysis

From the set of questionnaire variables (see table, Supplemental Digital Content 1, http://links.lww.com/ALN/A646), we selected potential PPC predictors, according to the investigators' consensus on measurable preoperative variables or the results of previous studies. 2,4,5,10 Independent continuous variables (age, oxygen saturation as measured by pulse oximetry $[\mathrm{Spo}_2]$, and duration of surgery) were previously grouped into categories based on the investigators' clinical understanding. The unadjusted association of all these variables was evaluated for categorical (chi-square test and Fisher exact test) variables. Bivariate odds ratios and 95% CI values were also estimated. To assess collinearity between categorical variables, the relationships between them was tested by the Cramer V test (between nominal variables) and Kendall tau (τ) β coefficient (between ordinal variables).

Before constructing the predictive logistic regression model, we randomly divided the sample into two parts: a

Table 1. Definitions of Postoperative Pulmonary Complications

Complication	Definition
Respiratory infection	When a patient received antibiotics for a suspected respiratory infection and met at least one of the following criteria ^{4,9,10} : new or changed sputum, new or changed lung opacities, fever, leukocyte count >12,000/μ
Respiratory failure	When postoperative Pao ₂ <60 mmHg on room air, a ratio of Pao ₂ to inspired oxygen fraction <300 or arterial oxyhemoglobin saturation measured with pulse oximetry <90% and requiring oxygen therapy
Pleural effusion	Chest x-ray demonstrating blunting of the costophrenic angle, loss of the sharp silhouette of the ipsilateral hemidiaphragm in upright position, evidence of displacement of adjacent anatomical structures, or (in supine position) a hazy opacity in one hemithorax with preserved
Atelectasis	vascular shadows ¹¹ Lung opacification with a shift of the mediastinum, hilum, or hemidiaphragm toward the affected area, and compensatory overinflation in the adjacent nonatelectatic lung ^{12,13}
Pneumothorax	Air in the pleural space with no vascular bed surrounding the visceral pleura ¹⁴
Bronchospasm	Newly detected expiratory wheezing treated with bronchodilators
Aspiration pneumonitis	Acute lung injury after the inhalation of regurgitated gastric contents ¹⁵

Pao₂ = partial pressure of oxygen in arterial blood.

development and a validation subsample. The development subsample (66.6% of patients) was used to construct the model and the validation subsample (33.3%) to confirm the model's discriminatory capability.

The logistic regression model was constructed using a backward stepwise selection procedure in which the presence of a PPC was the dependent variable. Independent predictors were entered into the model on the basis of the bivariate analysis (P < 0.05) and correlation coefficients between variables lower than 0.4. Potential predictors were sequentially removed if this exclusion did not result in a significant change in the log-likelihood ratio test. The cutoff for variable removal was set at a significance level of 0.05. We then calculated the adjusted odds ratios and the corresponding 95% CI values. The calibration of the logistic regression model was assessed by the Hosmer-Lemeshow goodness-of-fit statistic. To avoid overfitting the data for the development sample, a bootstrap method was used to find the best subset of factors. One thousand computer-generated samples, each in-

cluding 1,623 individuals (i.e., study subsample less one patient), were derived from the development subsample by random selection with replacement. Within each bootstrap sample, the β coefficient was calculated using all selected independent variables. The reliability of predictor variables in the final regression model was estimated by the 80% CI of the β coefficient in the bootstrap samples. Reliable predictors were expected to be retained if the 80% CI of bootstrap samples indicated statistical significance (P < 0.05). The model's discriminative performance was assessed by the c-statistic.

A simplified predictive risk score was then calculated by multiplying each logistic coefficient of regression (β) by 10 and rounding off its value. The simplified scores for development subsample cases were added together to produce an overall PPC risk score for each patient. To evaluate the ability of the model to predict increasing rates of PPC, we used that score and the minimum description length principle 16 to divide the subsample into three ranges reflecting low, medium, and high risk for PPC, each containing a similar number of patients with a PPC. Finally, to assess the discriminative performance of this risk score in both the development and validation subsamples, we used the c-statistic, which was also displayed graphically as the area under the receiver operating characteristic (ROC) curve. The Mann–Whitney U test was used to compare postoperative LOS between patients with and without a PPC. The Kruskal-Wallis test was used to compare postoperative LOS between groups according to the number of PPCs (0, 1, 2-3, or 4 or more). The Mantel-Haenszel test was used to analyze trend in mortality rates between groups formed according to the number of PPCs. Statistical analyses were performed using the SPSS software package (IBM SPSS Statistics 18, Chicago, IL); this version includes algorithms for performing bootstrapping procedures.

Quality Assurance

To evaluate the quality of recruitment and data collection, independent observers audited the medical records of a random sample of 150 patients (5% of the sample) from 12 randomly selected centers (4 community, 4 intermediate, and 4 major tertiary care hospitals). In every center, the number of patients audited was proportional to the number of patients recruited. It was found that the eligibility criteria were properly applied in all the audited centers. The data sample check included 130 items for each patient, encompassing all variables directly involved in the predictive model plus others; this data check found 379 instances of error or missing data (1.9% of the data audited), primarily involving time variables.

Results

Of 2,782 eligible patients, 313 were nonresponders or refused to participate, and 5 were lost to follow-up for the recording of outcome variables; thus, of those recruited, 88.6% participated. Nonparticipants were more likely than




Fig. 1. Recruitment flowchart. Communication difficulties were related mainly to a language barrier or cognitive disorders. Patients lost to follow-up for outcome were those with unknown outcome information in the postoperative period (one appendectomy, one herniorrhaphy, and three minor peripheral orthopedic procedures).

participants to have undergone emergency surgery (34% vs. 14%, P < 0.001) and to be current smokers (29% vs. 22%, P = 0.013) and older (mean [SD], 61 [20] yr vs. 58 [18] yr, P = 0.004). The final sample included in the statistical analysis, therefore, consisted of 2,464 inpatients (fig. 1). The characteristics of patients and procedures are detailed in table 2.

PPCs, LOS, and Mortality

A total of 242 PPCs were recorded in 123 patients (5.0% of the 2,464 studied patients). Postoperative respiratory failure developed in 63 patients (2.6%), bronchospasm in 44 (1.8%), pleural effusion in 43 (1.7%), respiratory infection in 40 (1.6%), atelectasis in 35 (1.4%), aspiration pneumonitis in 9 (0.4%), and pneumothorax in 8 (0.3%).

The median postoperative LOS was longer in patients with at least one PPC (12 days; 10-90th percentile, 4-36.8 days) than in those without a PPC (3 days; 10-90th percentile, 1-11 days). Thirty-five patients died within 30 days; 24 of these patients had at least one PPC (19.5% of the 123 patients with a PPC; 95% CI, 12.5-26.5%) and 11 had no PPC (0.5% of the 2,341 with no PPC; 95% CI, 0.2-0.8%). At 90 days, mortality was 24.4% (95% CI, 16.8–32.0%) of the 123 patients with at least one PPC and 1.2% (95% CI, 0.8-1.6%) of the 2,341 without a PPC (P < 0.001 for all comparisons).

The highest PPC rate was after cardiac surgery (39.6%), followed by thoracic (31.4%), abdominal (7.2%), and vascular procedures (5.8%). In absolute terms, the largest contribution came from abdominal surgery. Table 3 shows detailed information on the characteristics of PPCs, mortality, and postoperative ventilation management by specialties. Six of 1,336 patients who received general anesthesia required postoperative reintubation. Table 4 shows postoperative LOS and mortality by number of PPCs. Both of

Table 2. Demographic and Clinical Characteristics

Table 2: Bernographic and Olinical	Onaracteristics
Total No. (%) of patients	2,464 (100)
Male sex, n (%)	1,251 (50.8)
Age, median (10–90th	60 (31.6–80.0)
percentile), yr	- 4
Education, median (10-90th	9 (0–16)
percentile), yr	
Smoking status, n (%)	
Never smoker	1,230 (49.9)
Former smoker	729 (29.6)
Current smoker	505 (20.5)
Preoperative Spo ₂ , median	97 (94–99)
(10–90th percentile), %	07 (01 00)
	06.0 (01.5.00.4)
Body mass index, median	26.3 (21.5–29.4)
(10-90th percentile), kg/m ²	
COPD, n (%)	281 (11.4)
Respiratory infection in the	146 (5.9)
last month, n (%)	
ASA physical status, n (%)	
1	653 (26.5)
2	1,304 (52.9)
3	454 (18.4)
4	53 (2.2)
•	349 (14.2)
Emergency surgery, n (%)	349 (14.2)
Anesthesia, n (%)	1 000 (54.0)
General	1,336 (54.2)
Neuraxial/regional	1,128 (45.8)
Surgical specialty, n (%)	
Orthopedic	799 (32.4)
General and digestive	726 (29.5)
Urology	276 (11.2)
Gynecology	174 (7.1)
ENT	133 (5.4)
Vascular	104 (4.2)
Breast	93 (3.8)
Cardiac	53 (2.2)
Thoracic	35 (1.4)
Neurosurgery	26 (1.1)
Other	45 (1.7)
	1.8 (0.8–3.9)
Duration of surgery, median	1.6 (0.6–3.9)
(10-90th percentile), h	1 (0, 0)
Preoperative LOS, median	1 (0–2)
(10-90th percentile), d	
Postoperative LOS, median	3 (1–12)
(10-90th percentile), d	
30-day mortality, n (%)	35 (1.4)
90-day mortality, n (%)	59 (2.4)
	` '

ASA = American Society of Anesthesiologists; COPD = chronic obstructive pulmonary disease; ENT = ear, nose, and throat; LOS = length of stay; Spo_2 = oxyhemoglobin saturation by pulse oximetry breathing air in supine position.

these outcomes increased significantly as the number of PPCs increased.

Risk Factors and PPC Scoring

The results for independent variables that were entered into the logistic regression model are shown in table 5, along with significant variables that were rejected because of high collinearity with other independent variables (smoking status and chronic obstructive pulmonary disease). Alcohol intake, snoring, sleepiness, obesity, diabe-

tes, immunosuppression, intraoperative fluid therapy, and postoperative pain were unrelated ($P \ge 0.05$) to the presence of a PPC.

Multivariable logistic regression selected nine independent predictors of PPC: age, male sex, low preoperative SpO₂, acute respiratory infection during the month before surgery, preoperative anemia (hemoglobin concentration lower than 10 g/dl), positive cough test, upper abdominal or intrathoracic surgery, duration of procedure, and emergency surgery. Bootstrap validation (1,000 subsamples of 1,623 cases) indicated that 7 of those 9 independent predictors were present in more than 80% of bootstrap samples and thus were retained in the final model. The raw and adjusted odds ratios for the seven variables are shown in table 6, which also shows the simplified risk score derived from the β coefficient for each variable. This seven-variable regression model had good discrimination (c-statistic, 0.90) and calibration (Hosmer-Lemeshow P = 0.45) values. The ROC curves and the cstatistics for both the development and validation subsamples are presented in figure 2 (for the model using β coefficients) and figure 3 (for the model using the simplified risk score).

Table 7 shows the incidence of PPCs by risk score. The most relevant cut point was a simplified risk score of 26 (sensitivity 87.3% [95% CI, 77.7–94.0%], specificity 79.1% [95% CI, 77.0–81.1%]), which indicated moderate risk; a score greater than 45 indicated high risk (sensitivity 61.9% [95% CI, 49.7–73.2%], specificity 96.5% [95% CI: 95.5–97.4%]).

Discussion

The 5% incidence of PPCs that we observed in a broad, heterogeneous surgical population fell within the range reported.3,5 One of 5 patients who developed a PPC died within 30 days of surgery. Seven independent risk factors were finally selected in building a predictive score for PPC. Four patient-related factors (low preoperative Spo₂, recent respiratory tract infection, age, and low hemoglobin concentration) accounted for approximately 55% of the total risk score. The remaining three predictors were related to the surgical procedure (intrathoracic or upper abdominal surgery, duration of procedure, and emergency surgery) and accounted for 45% of the score. Good discriminative power for identifying patients at risk of a PPC was indicated by an area under the ROC curve of 90% for the simplified score. Three risk factors identified by our procedure, but not included in the evidence-based American College of Physicians guidelines,2 were low preoperative SpO2, recent respiratory infection, and preoperative anemia.

Predictors of PPC

Preoperative SpO₂ breathing room air in supine position was the strongest patient-related PPC risk factor. We consider this to be a highly useful finding because SpO₂ is an easily recorded objective measure. To our knowledge, this is the

31

7 (22.6)

117

27 (23.1)

	Operation of					
	General and Digestive	Cardiac	Orthopedic	Thoracic	Other	Total
Patients, n	726	53	799	35	851	2,464
Patients with at least 1 PPC, n (%)	52 (42.3)	21 (17.1)	19 (15.4)	11 (8.9)	20 (16.3)	123 (100)
Incidence of patients with at least 1 PPC within specialty, %	7.2	39.6	2.4	31.4	2.4	5.0
Patients with at least 1 PPC dead at 30 days, n (% of patients with PPC)	18 (34.6)	0 (0)	1 (5.3)	2 (18.2)	3 (15.0)	24 (19.5)
Patients with at least 1 PPC dead at 90 days, n (% of patients with PPC)	20 (38.5)	1 (4.8)	2 (10.5)	2 (18.2)	5 (25.0)	30 (24.4)

50

9 (18.0)

0(0)

Table 3. Characteristics of PPCs and Postoperative Mechanical Ventilation According to Surgical Specialties

27

11 (40.7)

PPC = postoperative pulmonary complication.

Patients with prolonged mechanical

ventilation after surgery, n Patients with prolonged mechanical

ventilation >24 h, n (%)

first time that preoperative SpO2 has been tested as a predictor. We found a strong association between PPCs and respiratory disease (respiratory symptoms), smoking (lifetime exposure), and heart failure (table 5), consistent with previous studies.² However, these factors were not selected as independent predictors on multivariable analysis, probably because SpO2 is a reflection of both respiratory and cardiovascular functional status.

A history of respiratory infection in the month before surgery, with fever and antibiotic treatment, encompasses both upper and lower airway infections. Each may have a different effect on morbidity. 18-20 Recent respiratory infections can cause local changes in airway reactivity, pulmonary function, and residual impairment of immunity induced by the infection itself or by antibiotic use. An increased risk of intraoperative respiratory events after an upper respiratory tract infection can persist for 4-6 weeks in children, especially if the trachea is intubated. 18,19 The ease with which such a history can be obtained from the patient and its high clinical value in predicting risk according to our findings suggest that it should be included in preoperative assessment. It might even be cause for postponing nonemergency surgery in some cases.

Age is a consistently reported predictor of PPCs, 10,20 and our findings confirm this. Furthermore, we found a clear deflection point (80 yr) at which the PPC rate increased markedly (odds ratio of 5.6 after this age). This observation is particularly relevant in Western countries where the population is aging and where surgery is being extended to patients who had formerly been excluded.

0(0)

Preoperative anemia (hemoglobin concentration lower than 10 g/dl) raised the risk for PPCs almost 3-fold, in agreement with recent studies identifying anemia as a predictor of poor outcome in critical and postoperative patients. Even minimal degrees of anemia are associated with a significant increase in the risk of 30-day postoperative mortality and cardiac events,²² although so far, there is no clear evidence that preoperative transfusion would reduce risk.

We confirmed that surgery-related risk factors are highly relevant.^{2,5} Those identified as independent predictors namely anatomical site (upper abdomen or intrathoracic incisions), duration of surgery longer than 2 h, and emergency surgery—are factors that, to some extent, can be controlled by surgeons in patients at high risk.

Many studies identify smoking and chronic obstructive pulmonary disease as risk factors for PPC.2 However, in our study, both showed a high level of collinearity with other factors. Current smokers had the lowest PPC rate in our study, whereas former smokers had the highest (see table 5). The reason for this finding might be that current smokers were on average 17 yr younger than former smokers. Lifetime exposure to smoking was chosen to enter the analysis because

Table 4. Postoperative LOS and Mortality According to the Number of PPCs

	No. of PPCs			Total No.	
	0	1	2–3	≥4	of Patients
No. (%) of patients Postoperative LOS, median (10–90th percentile), d*	2,341 (95.0)	66 (2.7)	37 (1.5)	20 (0.8)	2,464 (100)
	3 (1–11)	10 (3–26.5)	11 (3.8–27.8)	27 (10.4–105.1)	3 (1–12)
30-day mortality, n (%)†	11 (0.5)	6 (9.1)	11 (29.7)	7 (35.0)	35 (1.4)
90-day mortality, n (%)†	29 (1.2)	7 (10.6)	12 (32.4)	11 (55.0)	59 (2.4)

^{*} Kruskal-Wallis test for comparing means, P < 0.0001. † Mantel-Haenszel test for mortality trend, P < 0.0001. LOS = length of stay; PPC = postoperative pulmonary complication, a composite outcome in which 1 or more PPCs might be observed.

Table 5. Distribution of Results of Independent Variables in the Total Study Population of 2,464 Patients and the 123 Patients with at Least 1 PPC

Variables entered into the multiple regression model Hospital type Community 641 14 (2.2) 14 (2.2		No. of Patients	Missing Patients	No. (%) of Patients with ≥1 PPC	P Value
Hospital type	ariables entered into the multiple regression				
Community 641 Intermediate referral Intermediate referral Major tertlary care 1,083 51 (4.7) style (
Intermediate referral 1,083 51 (4.7) 58 (7.8) 58 (7.8) 58 (7.8) 58 (7.8) 58 (7.8) 58 (7.8) 58 (7.8) 58 (7.8) 58 (7.8) 58 (7.8) 58 (7.8) 58 (7.8) 58 (7.8) 58 (7.8) 58 (7.8) 58 (8.9) 73 (3.0)		0.44	0	4.4.(0.0)	< 0.001
Major tertiary care 740 58 (7.8)				14 (2.2) 51 (4.7)	
Sex Male 1,251 86 (6.9) Female Age, yr 37 (3.0) Age, yr ≤50 804 17 (2.1) 51=80 250 31 (12.4) Education, yr 2 250 ≤12 1,836 106 (5.8) ≤12 1,836 106 (5.8) ≤12 1,836 17 (2.7) Functional status 0 17 (2.7) Independent 2,212 99 (4.5) Fartially or totally dependent 252 24 (9.5) Smokers: lifetime pack-year, n 2 2 0 1,230 46 (3.7) 1 -40 935 38 (4.1) > 40 297 39 (13.1) Respiratory symptoms (cough, sputum, dyspnea, wheezing), n 1 4 (3.2) 1 -2 833 4 (4.5.3) 3 (4.1) 3 -2 833 4 (5.3) 3 (4.5) 3 -2 833 4 (4.5.3) 3 (4.5) 1 -2 833 4 (5.3) 3 (5.1.2) Asthma				51 (4.7) 58 (7.8)	
Male Female 1,251 86 (6.9) Female 1,213 37 (3.0) Age, yr 0 0 550 804 17 (2.1) 51-80 250 31 (12.4) Education, yr 2 2 =12 626 17 (2.7) Functional status 0 0 Independent 22 12 99 (4.5) Partially or totally dependent 252 24 (9.5) Smokers: lifetime pack-year, n 2 2 0 1,230 46 (3.7) 3-40 3955 38 (4.1) >40 9355 38 (4.1) >40 9355 38 (4.1) >40 9355 38 (4.1) >40 9355 38 (4.1) >40 9355 38 (4.1) >40 9355 38 (4.1) 3-2 833 44 (5.2) 3-4 383 44 (5.2) 3-4 38 (3.3) 44 (5.2) 4-1 2		7 40	0	30 (7.0)	< 0.001
Age, yr 0 17 (2.1) ≤50 1,410 75 (6.3) 51-80 1,410 75 (6.3) ≥80 250 31 (12.4) ≤12 626 17 (2.7) >-12 626 17 (2.7) Functional status 0 17 (2.7) Independent 2,212 99 (4.5) Partially or totally dependent 252 24 (9.5) Smokers: lifetime pack-year, n 2 2 46 (3.7) 1-40 935 38 (4.1) 39 (13.1) Respiratory symptoms (cough, sputum, dyspnea, wheezing), n 297 39 (13.1) Respiratory symptoms (cough, sputum, dyspnea, wheezing), n 1 44 (3.2) 1 297 39 (13.1) Respiratory symptoms (cough, sputum, dyspnea, wheezing), n 1 1364 44 (3.2) 1 297 39 (13.1) 13.1 Respiratory symptoms (cough, sputum, dyspnea, dyspne		1,251	· ·	86 (6.9)	10.00
\$\frac{\sis6}{56}\$ 804	Female	1,213		37 (3.0)	
51-80 1,410 75 (6.3) ≥80 250 31 (12.4) Education, yr 2 1 ≤12 626 17 (2.7) Functional status 0 10 Independent 2,212 99 (4.5) Partially or totally dependent 252 24 (9.5) Smokers: lifetime pack-year, n 1230 2 0 1,364 46 (3.7) 1-40 935 38 (4.1) >40 297 39 (13.1) Respiratory symptoms (cough, sputum, dyspnea, wheezing), n 1 3 0 1,364 44 (3.2) 1-2 833 44 (5.3) 3-4 266 35 (13.2) Astma 0 10 No 2,315 110 (4.8) Yes 149 13 (8.7) Other respiratory diseases 0 94 (3.3) No 2,322 99 (4.3) Yes 142 24 (16.9) Cough test* 8 14 (4.0)<	Age, yr	004	0	47 (0.4)	< 0.001
>80 250 31 (12.4) Education, yr 2 ≤12 1,836 106 (5.8) >12 626 17 (2.7) Functional status Independent 2,212 99 (4.5) Independent 252 24 (9.5) Smokers: lifetime pack-year, n 20 46 (3.7) 1 -40 935 38 (4.1) >40 297 39 (13.1) Respiratory symptoms (cough, sputum, dyspnea, wheezing), n 1 364 44 (3.2) 1 -2 833 44 (5.3) 3 -4 266 35 (13.2) Asthma 0 110 (4.8) No 2,315 110 (4.8) Yes 142 24 (16.9) Other respiratory diseases 149 13 (8.7) No 2,322 99 (4.3) Yes 142 24 (16.9) Cough test* 8 14(10.9) Negative 2,019 81 (4.0) Positive 437 38 (8.7) Respiratory infection in the last month 1 76 No 2,317 97 (4.2) Yes 146 26 (17.8) Preoperative Spo ₂ , % 2 66 (3.0) ≤96 1,887				1 / (2.1)	
Education, yr ≤12					
≤12 1,836 106 (5.8) >12 626 17 (2.7) Functional status 0 17 (2.7) Independent 2,212 99 (4.5) Partially or totally dependent 252 24 (9.5) Smokers: lifetime pack-year, n 2 46 (3.7) 1 -40 935 38 (4.1) >40 297 39 (13.1) Respiratory symptoms (cough, sputum, dyspnea, wheezing), n 1 1 0 1,364 44 (3.2) 1 -2 833 44 (5.3) 3 -4 266 35 (13.2) Asthma 0 2,315 110 (4.8) Yes 149 13 (8.7) Other respiratory diseases 0 140 (1.8) No 2,322 99 (4.3) Yes 142 24 (16.9) No 2,322 99 (4.3) Yes 142 24 (16.9) Respiratory infection in the last month 1 1 No 2,317 97 (4.2)		250	2	31 (12.4)	0.002
Signature Sign		1,836	_	106 (5.8)	0.002
Independent Partially dependent 252 24 (9.5) Partially or totally dependent 252 24 (9.5) Smokers: lifetime pack-year, n 0 1,230 46 (3.7) 1-40 935 38 (4.1) >40 297 39 (13.1) Respiratory symptoms (cough, sputum, dyspnea, wheezing), n 0 1,364 44 (3.2) 1-2 833 44 (5.3) 1-2 833 44 (5.3) 3-4 266 35 (13.2) Asthma 266 0 31.3 (8.7) No 2,315 110 (4.8) Yes 149 13 (8.7) Other respiratory diseases 0 No 2,322 99 (4.3) Yes 142 24 (16.9) Cough test* 8 81 (4.0) Negative 2,019 81 (4.0) Positive 437 38 (8.7) Respiratory infection in the last month 1 1 26 (17.8) No 2,317 97 (4.2) Yes 146 26 (17.8) Preoperative Spo₂, % 2 26 (17.8) ≥96 1,887 56 (3.0) 91-95 519 51 (9.8) ≥90 56 16 (28.6) Active oncologic disease in the last 5 yr No 2,069 83 (4.0) Yes 395 40 (10.1) Heart failure 0 No 2,273 89 (3.9) Yes 395 40 (10.1) Heart failure 0 No 1,591 61 (3.8) Yes 873 62 (7.1) No 1,591 61 (3.8) Yes 873 62 (7.1) Repal failure† 0 No 1,591 61 (3.8) Yes 873 62 (7.1) No 1,591 No 1,24 (7.1) Yes 873 112 (4.7) No 2,378 112 (4.7) Yes 873 9 (9.7) No 2,378 112 (4.7) No 2,378 112 (4.7) Yes 9 (3.7) 114 (4.8) No 2,376 9 (9.7) Liver disease No 2,356 113 (4.8) No 2,356 113 (4.8) No 2,356 113 (4.8)	>12				
Partially or totally dependent Smokers: lifetime pack-year, n 0 1,230 2 46 (3.7) 1-40 935 38 (4.1) >>40 297 39 (13.1) Respiratory symptoms (cough, sputum, dyspnea, wheezing), n 0 1,364 44 (3.2) 1-2 833 44 (5.3) 3-4 266 35 (13.2) Asthma 0 110 (4.8) Yes 149 13 (8.7) Other respiratory diseases No 2,315 110 (4.8) Yes 142 24 (16.9) Cough test* Negative 2,019 81 (4.0) Positive 437 38 (8.7) Respiratory infection in the last month No 2,317 97 (4.2) Yes 146 26 (17.8) Preoperative Spo ₂ , % ≥96 1,887 56 (3.0) ≥90 56 16 (28.6) Active oncologic disease in the last 5 yr No 2,069 83 (4.0) Yes 191 95 51 (9.8) ≤90 56 16 (28.6) Active oncologic disease in the last 5 yr No 2,273 89 (3.9) Yes 191 34 (17.8) Coronary artery disease No 1,591 34 (17.8) Coronary artery disease No 1,591 61 (3.8) Yes 191 34 (17.8) Coronary artery disease No 2,289 101 (4.4) Yes 873 66 111 (12.8) No 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† No 2,378 112 (4.7) No (2,378 112 (4.7) Yes 86 11 (12.8) No (2,371 114 (4.8) Yes 86 11 (12.8) No (2,371 114 (4.8) Yes 9 86 11 (12.8) No (2,371 114 (4.8) Yes 9 9 9 (9.7) Liver disease No 2,356 113 (4.8)			0	/	< 0.001
Smokers: lifetime pack-year, n 2 46 (3.7) 1 -40 935 38 (4.1) >40 297 39 (13.1) Respiratory symptoms (cough, sputum, dyspnea, wheezing), n 1 0 1,364 44 (3.2) 1 -2 833 44 (5.3) 3 -4 266 35 (13.2) Asthma 0 110 (4.8) No 2,315 110 (4.8) Yes 149 13 (8.7) Other respiratory diseases 0 10 (4.8) No 2,322 99 (4.3) Yes 142 24 (16.9) Cough test* 8 81 (4.0) Negative 2,019 81 (4.0) Pespiratory infection in the last month 1 70 (4.2) No 2,317 97 (4.2) Yes 146 26 (17.8) Preoperative Spo ₂ , % 2 2 ≥96 1,817 56 (3.0) 91-95 519 51 (9.8) ≤90 56 16 (28					
0 1.40 935 38 (4.1)		252	0	24 (9.5)	<0.001
1-40		1 230	2	46 (3.7)	< 0.001
Sespiratory symptoms (cough, sputum, dyspnea, wheezing), n				38 (4 1)	
Respiratory symptoms (cough, sputum, dyspnea, wheezing), n 1 0 1,364 44 (3.2) 1-2 833 44 (5.3) 3-4 266 35 (13.2) Asthma 0 No 2,315 110 (4.8) Yes 149 13 (8.7) Other respiratory diseases 0 13 (8.7) No 2,322 99 (4.3) Yes 142 24 (16.9) Cough test* 8 8 Negative 2,019 81 (4.0) Positive Posit					
0 ° 1 1,364 44 (3.2) 1-2 833 44 (5.3) 3-4 266 35 (13.2) Asthma 0 No 2,315 110 (4.8) Yes 149 13 (8.7) Other respiratory diseases 0 99 (4.3) No 2,322 99 (4.3) Yes 142 24 (16.9) Cough test* 8 38 (8.7) Negative 2,019 81 (4.0) Positive 437 38 (8.7) Respiratory infection in the last month 1 97 (4.2) No 2,317 97 (4.2) Yes 146 26 (17.8) Preoperative Spo ₂ , % 2 2 ≥96 1,887 56 (3.0) 91-95 519 51 (9.8) ≤90 6 16 (28.6) Active oncologic disease in the last 5 yr 0 83 (4.0) Yes 395 40 (10.1) Heart failure 0 0 No 2,273 89 (3.9) Yes 175	Respiratory symptoms (cough, sputum,		1	,	< 0.001
1-2 833 44 (5.3) 3-4 266 35 (13.2) Asthma No No 2,315 110 (4.8) Yes 149 113 (8.7) Other respiratory diseases No No 2,322 99 (4.3) Yes 142 24 (16.9) Cough test* Negative No Positive Respiratory infection in the last month No 2,317 Yes 146 26 (17.8) Preoperative Spo₂, % 296 297 (4.2) 297 (4.2) 29 (16.9) 81 (4.0) 29 (16.9) 81 (4.0) 29 (17.8	dyspnea, wheezing), n				
Asthma No No No 2,315 110 (4.8) Yes 149 13 (8.7) Other respiratory diseases No Yes 149 13 (8.7) Other respiratory diseases No Yes 142 24 (16.9) Cough test* Negative Positive No 147 Respiratory infection in the last month No 2,317 Yes 146 266 18 (4.0) Positive Respiratory disease No 1 (4.0) Positive 1 (4.0) Prositive 1 (4.0) 1 (4.2) 1 (4.2) 2 (4 (16.9)					
Asthma No No No Yes 149 113 (8.7) Other respiratory diseases No No So So So No So					
No Yes 149 110 (4.8) Yes 2,322 99 (4.3) Yes 2,322 99 (4.6.9) Cough test* 8		266	0	35 (13.2)	0.000
Yes 149 13 (8.7) Other respiratory diseases 0 99 (4.3) No 2,322 99 (4.3) Yes 142 24 (16.9) Cough test* 8 8 Negative 2,019 81 (4.0) Positive 437 38 (8.7) Respiratory infection in the last month 1 No 2,317 97 (4.2) Yes 146 26 (17.8) Preoperative Spo ₂ , % 2 ≥96 1,887 56 (3.0) 91-95 519 51 (9.8) ≤90 56 16 (28.6) Active oncologic disease in the last 5 yr 0 No 2,069 33 (4.0) Yes 395 40 (10.1) Heart failure 0 83 (4.0) No 2,273 89 (3.9) Yes 191 34 (17.8) Coronary artery disease 0 101 (4.4) No 2,289 101 (4.4) Yes 873 62 (7.1) Renal failure† 0 112 (4.7)		2 315	U	110 (4.8)	0.033
Other respiratory diseases 0 4 No 2,322 99 (4.3) Yes 142 24 (16.9) Cough test* 8 8 Negative 2,019 8 (4.0) Positive 437 38 (8.7) Respiratory infection in the last month 1 97 (4.2) Yes 146 26 (17.8) Preoperative Spo ₂ , % 2 2 ≥96 1,887 56 (3.0) 91-95 519 51 (9.8) ≤90 56 16 (28.6) Active oncologic disease in the last 5 yr 0 83 (4.0) Yes 395 40 (10.1) Heart failure 0 89 (3.9) Yes 191 34 (17.8) Coronary artery disease 191 34 (17.8) No 2,289 101 (4.4) Yes 175 22 (12.6) Hypertension 0 1,591 61 (3.8) No 2,378 112 (4.7) Yes <					
No Yes 142 24 (16.9) Cough test* 8 Negative 2,019 81 (4.0) Positive 437 38 (8.7) Respiratory infection in the last month No 2,317 97 (4.2) Yes 146 26 (17.8) Preoperative Spo₂, % 2 ≥96 1,887 56 (3.0) 91-95 519 51 (9.8) ≤90 56 16 (28.6) Active oncologic disease in the last 5 yr No 2,069 83 (4.0) Yes 395 40 (10.1) Heart failure 0 No 2,273 89 (3.9) Yes 191 34 (17.8) Coronary artery disease No 2,289 101 (4.4) Yes 175 22 (12.6) Hypertension 0 No 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 No 2,378 112 (4.7) Yes 86 11 (12.8) Neurologic disease No 2,378 11 (12.8) Neurologic disease No 2,371 114 (4.8) Yes 93 99.7) Liver disease No 2,356 113 (4.8)		. 10	0	10 (0.17)	< 0.001
Cough test* 8 Negative 2,019 81 (4.0) Positive 437 38 (8.7) Respiratory infection in the last month 1 797 (4.2) Yes 146 26 (17.8) Preoperative Spo₂, % 2 2 ≥96 1,887 56 (3.0) 91-95 519 51 (9.8) ≤90 56 16 (28.6) Active oncologic disease in the last 5 yr 0 83 (4.0) No 2,069 83 (4.0) Yes 395 40 (10.1) Heart failure 0 89 (3.9) Yes 191 34 (17.8) Coronary artery disease 0 101 (4.4) Yes 175 22 (12.6) Hypertension 0 0 No 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 No 2,378 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 No 2,371 114 (4.8)	No				
Negative Positive 2,019 437 81 (4.0) 38 (8.7) Respiratory infection in the last month No 2,317 7 yes 1 97 (4.2) 7 (4.2) Yes 26 (17.8) 146 26 (17.8) 26 (17.8) Preoperative Spo2, % 2 2 ≥96 1,887 55 (3.0) 91–95 519 519 51 (9.8) 55 (3.0) 91–95 51 (9.8) 91.0 ≤90 56 16 (28.6) Active oncologic disease in the last 5 yr 0 83 (4.0) 91.0 No Yes 395 40 (10.1) 40 (10.1) 97.0 97.0 Heart failure No 2,273 89 (3.9) 89 (3.9) 92.0 99.0 99.0 Yes 191 34 (17.8) 34 (17.8) 99.0 99.0 99.7 Coronary artery disease No 1,591 32 (2.2) 61 (3.8) 92.0 99.7 <td></td> <td>142</td> <td>_</td> <td>24 (16.9)</td> <td></td>		142	_	24 (16.9)	
Positive Respiratory infection in the last month No 2,317 Yes 146 26 (17.8) Preoperative Spo₂, % ≥96 1,887 ≥90 Active oncologic disease in the last 5 yr No Yes 12 2,069 305 40 (10.1) Heart failure No No 2,273 No Yes 191 Coronary artery disease No No No 1,591 No No 1,591 No No 1,591 No No No 1,591 No No No 1,591 Renal failure† No No 1,591 Renal failure† No No 2,378 No Yes 86 11 (12.8) Neurologic disease No No Yes 12 (17.1) Renal failure† No No 2,378 No Yes 10 No No 2,378 No Yes 11 (12.8) Neurologic disease No No 2,371 Yes No No 2,371 No No 2,371 No Yes No No No 2,371 No Yes No No No 2,371 No Yes No No No 2,371 No	Cough test*	0.040	8	04 (4.0)	< 0.001
Respiratory infection in the last month 1 97 (4.2) No 2,317 97 (4.2) Yes 146 26 (17.8) Preoperative Spo₂, % 2 ≥96 1,887 56 (3.0) 91-95 519 51 (9.8) ≤90 56 16 (28.6) Active oncologic disease in the last 5 yr 0 No 2,069 83 (4.0) Yes 395 40 (10.1) Heart failure 0 No 2,273 89 (3.9) Yes 191 34 (17.8) Coronary artery disease 0 89 (3.9) No 2,289 101 (4.4) Yes 175 22 (12.6) Hypertension 0 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 114 (4.8) No 2,371 114 (4.8) Yes 9 9 (9.7) Liver disease 0 11					
No 2,317 97 (4.2) Yes 146 26 (17.8) Preoperative Spo₂, % 2 ≥96 1,887 56 (3.0) 91–95 519 51 (9.8) ≤90 56 16 (28.6) Active oncologic disease in the last 5 yr 0 No 2,069 83 (4.0) Yes 395 40 (10.1) Heart failure 0 89 (3.9) Yes 191 34 (17.8) Coronary artery disease 0 101 (4.4) Yes 175 22 (12.6) Hypertension 0 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 1 No 2,378 11 (12.8) Neurologic disease 0 11 (12.8) Neurologic disease 0 114 (4.8) No 2,371 114 (4.8) Yes 9 9 (9.7) Liver disease 0 113 (4.8)		407	1	30 (0.7)	< 0.001
Yes 146 26 (17.8) Preoperative Spo₂, % 2 ≥96 1,887 56 (3.0) 91-95 519 51 (9.8) ≤90 56 16 (28.6) Active oncologic disease in the last 5 yr 0 No 2,069 83 (4.0) Yes 395 40 (10.1) Heart failure 0 89 (3.9) Yes 191 34 (17.8) Coronary artery disease 0 0 No 2,289 101 (4.4) Yes 175 22 (12.6) Hypertension 0 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 12 (4.7) No 2,378 11 (12.8) Neurologic disease 0 11 (12.8) No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 113 (4.8)		2.317		97 (4.2)	νο.σσ1
≥96					
91-95 519 51 (9.8) ≤90 56 16 (28.6) Active oncologic disease in the last 5 yr 0 No 2,069 83 (4.0) Yes 395 40 (10.1) Heart failure 0 No 2,273 89 (3.9) Yes 191 34 (17.8) Coronary artery disease 0 34 (17.8) No 2,289 101 (4.4) Yes 175 22 (12.6) Hypertension 0 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 112 (4.7) No 2,378 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 114 (4.8) No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)	Preoperative Spo ₂ , %		2		< 0.001
≤90 56 16 (28.6) Active oncologic disease in the last 5 yr 0 No 2,069 83 (4.0) Yes 395 40 (10.1) Heart failure 0 No 2,273 89 (3.9) Yes 191 34 (17.8) Coronary artery disease 0 34 (17.8) No 2,289 101 (4.4) Yes 175 22 (12.6) Hypertension 0 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 114 (4.8) No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)					
Active oncologic disease in the last 5 yr No Yes No Yes 395 40 (10.1) Heart failure No No 2,273 89 (3.9) Yes 191 Coronary artery disease No Yes 191 2,289 No Yes 175 22 (12.6) Hypertension No No 1,591 Yes 873 62 (7.1) Renal failure† No Yes No 2,378 No Yes No 2,378 No Yes No No 2,378 No Yes No No 2,378 No Yes No No 2,371 Yes No Yes No No 2,371 Yes No Yes N				51 (9.8) 16 (28.6)	
No 2,069 83 (4.0) Yes 395 40 (10.1) Heart failure 0 89 (3.9) No 2,273 89 (3.9) Yes 191 34 (17.8) Coronary artery disease 0 101 (4.4) No 2,289 101 (4.4) Yes 175 22 (12.6) Hypertension 0 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 114 (4.8) No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 113 (4.8)	Active oncologic disease in the last 5 vr	30	0	10 (20.0)	< 0.001
Yes 395 40 (10.1) Heart failure 0 No 2,273 89 (3.9) Yes 191 34 (17.8) Coronary artery disease 0 No 2,289 101 (4.4) Yes 175 22 (12.6) Hypertension 0 No 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 114 (4.8) Yes 93 9 (9.7) Liver disease 0 113 (4.8)		2.069	Ü	83 (4.0)	νο.σσ1
No 2,273 89 (3.9) Yes 191 34 (17.8) Coronary artery disease 0 No 2,289 101 (4.4) Yes 175 22 (12.6) Hypertension 0 No 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 No 2,378 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)	Yes				
Yes 191 34 (17.8) Coronary artery disease 0 No 2,289 101 (4.4) Yes 175 22 (12.6) Hypertension 0 No 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 0 No 2,378 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)			0		< 0.001
Coronary artery disease 0 No 2,289 101 (4.4) Yes 175 22 (12.6) Hypertension 0 No 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 No 2,378 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)					
No 2,289 101 (4.4) Yes 175 22 (12.6) Hypertension 0 No 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 No 2,378 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)		191	0	34 (17.8)	< 0.001
Yes 175 22 (12.6) Hypertension 0 No 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 No 2,378 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)		2 289	U	101 (4.4)	<0.001
Hypertension 0 No 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 112 (4.7) No 2,378 11 (12.8) Neurologic disease 0 114 (4.8) No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 113 (4.8)					
No 1,591 61 (3.8) Yes 873 62 (7.1) Renal failure† 0 No 2,378 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)			0	(:_:-)	< 0.001
Renal failure† 0 No 2,378 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)	No	1,591			
No 2,378 112 (4.7) Yes 86 11 (12.8) Neurologic disease 0 No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)		873		62 (7.1)	
Yes 86 11 (12.8) Neurologic disease 0 No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)		0.070	0	110 (4.7)	0.003
Neurologic disease 0 No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)					
No 2,371 114 (4.8) Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)		00	Ο	11 (12.0)	0.047
Yes 93 9 (9.7) Liver disease 0 No 2,356 113 (4.8)		2.371	J	114 (4.8)	5.047
Liver disease 0 113 (4.8)	Yes				
	Liver disease		0		0.037
VAC 102 10 2\					
	Yes	108		10 (9.3)	(continued)

Table 5. Continued

	No. of Patients	Missing Patients	No. (%) of Patients with \geq 1 PPC	P Value
Preoperative anemia‡		0		<0.001
No	2,305	· ·	105 (4.6)	(0.001
Yes	159		18 (11.3)	
Preoperative nasogastric tube	0.070	0	405 (4.4)	< 0.001
No Yes	2,378 86		105 (4.4) 18 (20.9)	
Preoperative length of stay, d	00	0	10 (20.9)	< 0.001
<2	2,156	· ·	81 (3.8)	
≥2	308		42 (13.6)	
Type of surgery	0.115	0	00 (4.4)	< 0.001
Scheduled Emergency	2,115 349		93 (4.4) 30 (8.6)	
Anesthesia	349	0	30 (8.0)	< 0.001
Regional (neuraxial or plexus)	1,128	· ·	23 (2.0)	
General	1,336		100 (7.5)	
Surgical incision		0		< 0.001
Peripheral	2,013		45 (2.2)	
Upper abdominal Intrathoracic	361 90		44 (12.2) 34 (37.8)	
Surgical invasiveness§	90	0	34 (37.8)	< 0.001
1–2 (low)	1,605	Ü	24 (1.5)	νο.σσ.
3 (intermediate)	711		54 (7.6)	
4–5 (high)	148		45 (30.4)	
Intraoperative nasogastric tube	0.074	0	FF (0.7)	< 0.001
No Yes	2,074 390		55 (2.7) 68 (17.4)	
Intraoperative bladder catheter	390	1	08 (17.4)	< 0.001
No	1,524	•	27 (1.8)	νο.σσ.
Yes	939		96 (10.2)	
Preoperative prophylaxis with antibiotics		1		< 0.001
No Yes	669		12 (1.8)	
Intraoperative blood transfusion	1,794	3	111 (6.2)	< 0.001
No	2,348	0	100 (4.3)	<0.001
Yes	113		22 (19.5)	
Intraoperative pulmonary complications		0		< 0.001
No	2,213		81 (3.7)	
Yes	251	0	42 (16.7)	< 0.001
Intraoperative cardiovascular complications No	2,022	U	72 (3.6)	<0.001
Yes	442		51 (11.5)	
Duration of surgery, h		0	- ()	< 0.001
≤2 h	1,958		48 (2.5)	
>2 to 3 h	272		25 (9.2)	
>3 h	234		50 (21.4)	
Significant variables not entered into the multiple				
regression model due to high collinearity				
ASA physical status	GEO	0	10 /1 E\	< 0.001
2	653 1,304		10 (1.5) 29 (2.2)	
3	454		64 (14.1)	
4	53		20 (37.7)	
Smoking status		0		< 0.001
Never smoker	1,230		46 (3.7)	
Former smoker Current smoker	729 505		65 (8.9)	
COPD	303	0	12 (2.4)	< 0.001
No	2,183	J	77 (3.5)	\J.001
Yes	281		46 (16.4)	

^{*} In the cough test, the patient is asked to take a deep breath and cough once. A positive test is defined by repeated coughing after the first cough.\(^10 \) † Renal failure, defined as serum creatinine >2.5 mg/dl. \(\pm\$ Preoperative anemia, defined as hemoglobin <10 g/dl. \(\pm\$ Scoring as described by Holt and Silverman.\(^17\)

ASA = American Society of Anesthesiologists; COPD = COPD

Table 6. Independent Predictors of Risk for PPCs Identified in the Logistic Regression Model

	Multivariate Analysis OR (95% CI) n = 1,624*	eta	Risk Score†
A G G G G W G	,		·
Age, yr ≤50	1		
_51 _ 80	1.4 (0.6–3.3)	0.331	3
>80	5.1 (1.9–13.3)	1.619	16
Preoperative	(
Spo ₂ , %			
≥96	1		
91–95	2.2 (1.2-4.2)	0.802	8
≤90	10.7 (4.1–28.1)	2.375	24
Respiratory	5.5 (2.6–11.5)	1.698	17
infection in			
the last month	0.0 (4.4.6.5)	1 105	4.4
Preoperative anemia	3.0 (1.4–6.5)	1.105	11
anema (≤10 g/dl)			
Surgical incision			
Peripheral	1		
Upper	4.4 (2.3–8.5)	1.480	15
abdominal	(/		
Intrathoracic	11.4 (4.9-26.0)	2.431	24
Duration of			
surgery, h			
≤2	1		
>2 to 3	4.9 (2.4–10.1)	1.593	16
>3	9.7 (4.7–19.9)	2.268	23
Emergency	2.2 (1.0–4.5)	0.768	8
procedure			

 $^{^*}$ Because of a missing value for some variables, three patients were excluded. Logistic regression model constructed with the development subsample, c-index = 0.90; Hosmer-Lemeshow chi-square test = 7.862; P=0.447. † The simplified risk score was the sum of each β logistic regression coefficient multiplied by 10, after rounding off its value.

 $CI = confidence interval; OR = odds ratio; PPC = postoperative pulmonary complications; <math>Spo_2 = oxyhemoglobin saturation by pulse oximetry breathing air in supine position.$

exposure in excess of 40 pack-years was associated with higher risk in the bivariate analysis; nonetheless, the independence of this factor was not confirmed, so it was removed. With regard to chronic obstructive pulmonary disease, it is important to take into account that when this disease is mentioned in a patient's chart, it is often based on clinical criteria rather than a confirmed spirometric diagnosis.²³ For this reason, we considered that respiratory symptoms, which are easily recorded during the preanesthetic consultation by means of the Medical Research Council questionnaire, 24 would perhaps provide a better candidate for inclusion in the regression analysis. Furthermore, there is some suggestion in the literature that the larger the number of abnormal clinical findings present, the more severe the obstructive lung disease will probably be. 25,26 However, respiratory symptoms also failed to emerge as an independent factor on multivariable analysis.




Fig. 2. Receiver operating characteristic (ROC) curve drawn for the model built using β coefficients. Development subsample, c-statistic for the area under the ROC curve (AUC) = 0.90 (95% confidence interval [CI], 0.85–0.94); validation subsample, c-statistic for the AUC = 0.88 (95% CI, 0.84–0.93).

Study Strengths and Limitations

A strength of the current study was its prospective, population-based, multicenter design. We collected data for a representative random sample of surgical patients undergoing




Fig. 3. Receiver operating characteristic (ROC) curve drawn using the simplified risk score. Development subsample, c-statistic for the area under the ROC curve (AUC) = 0.89 (95% confidence interval [CI], 0.83-0.93); validation subsample, c-statistic for the AUC = 0.84 (95% CI, 0.77-0.90). The simplified risk score was obtained by multiplying the logistic regression β coefficient by 10 and rounding off its value.

Table 7. PPC Risk Score: Distribution of Patients and Rates by Intervals

	Risk Score Intervals*			
	Low Risk <26 Points	Intermediate Risk 26-44 Points	High Risk ≥45 Points	
Development subsample, No. (%) of patients†	1,238 (76.2)	288 (17.7)	98 (6.0)	
Validation subsample, No. (%) of patients	645 (77.1)	135 (16.1)	57 (6.8)	
PPC rate, development subsample, % (95% CI)	0.7 (0.2–1.2)	6.3 (3.5–9.1)	44.9 (35.1–54.7)	
PPC rate, validation subsample, % (95% CI)	1.6 (0.6–2.6)	13.3 (7.6–19.0)	42.1 (29.3–54.9)	

^{*} Risk intervals were based on division of the development subsample into optimal risk intervals, according to the simplified risk score and applying the minimum description length principle. † Three patients were excluded because of a missing value in some variable. CI = confidence interval; PPC = postoperative pulmonary complication.

routine anesthetic procedures for each type of surgery during the course of a year and throughout an extensive geographic area that included rural, semirural, and urban populations with wide-ranging health and social status. We decided to include patients undergoing cardiac surgery because they make up a substantial part of the surgical caseload and have both procedure-related and other risk factors common to all surgical patients (see table 3). A recent study of a large general surgical population reported a mortality rate for cardiac surgery that was lower than the average for all surgical procedures,²⁷ suggesting that it need not be singled out as a special higher-risk setting a priori. We did exclude patients undergoing procedures of very low complexity, performed on an outpatient basis, or involving only peripheral or local anesthesia. We consider that by applying these inclusion and exclusion criteria, we accomplished our goal of taking an approach that would be relevant to the real world of anesthetics and surgery in which PPCs are a serious threat.

A limitation of our study was that the sample size was not large enough to develop adequately a multivariable regression model in which 33 predictors were entered. For this reason, after performing the multivariable analysis, we resampled the development subsample using a bootstrapping technique. The purpose was to avoid overfitting and to estimate the stability of the dataset. As a result, seven of nine variables initially identified by multivariable regression were retained in the model. Only those seven variables were then used to build up the predictive index. Alternatively, based on the performance of the model in the validation subsample, it would also be possible to propose a parsimonious model with only three factors because such a reduced model would preserve much of the predictive power of the seven-factor model. In fact, the three most powerful variables (i.e., Spo₂, surgical incision, and duration of surgery) give an area under the ROC curve of more than 0.87. However, various other combinations of three risk factors would likewise give high c-statistics such that the clinical utility of one three-factor model would not be clearly greater than the utility of another one. We, therefore, chose to emphasize the clinical interest of the full range of seven relevant variables identified in the development subsample, given the ease with which information on all these factors can be obtained in most settings and because some of them can be preoperatively managed. The use of this seven-variable model also allowed us to stratify PPC risk on three levels (table 7).

Another possible limitation is our definition of PPC. A more stringent definition would probably have increased the impact of PPC on mortality and postoperative LOS. However, we chose to follow the approach of most PPC studies to date in which risk is established for a composite outcome,² one that can occur in the presence of any of several or all of a list of complications. We observed that removing individual PPCs from the composite did not have an appreciable effect on the prediction capacity. For example, if we were to remove bronchospasm from the composite outcome, the area under the ROC curve would change only slightly, from 0.90 to 0.89 in the development subsample. Furthermore, it is worth noting that even the appearance of a single PPC among those that comprise the composite was independently associated with increased LOS and mortality (table 4).

A third potential limitation of the study was the participation of more than 200 recorders of data in 59 hospitals. However, we took measures to avoid inconsistencies and designed a questionnaire that addressed major medical conditions. We also conducted training sessions for the investigators and checked for and ruled out an effect of center. A fourth potential limitation was that in some centers, the observers were also the anesthesiologists in charge of patient care. We, therefore, included a quality assurance step in which medical records were checked by independent auditors to assure compliance with instructions. A fifth limitation was that the characteristics of nonresponders suggest that the PPC incidence may have been underestimated in patients who were older, who were smokers, or who underwent emergency surgery. The high response rate, however, means that the effect of this unavoidable methodological problem would be minimal.

Finally, we must also be concerned about possible imprecision in the definition of some preexisting conditions, given that diagnoses were established from the medical records or patient interviews. We felt that, for the purpose of this study, the recorded clinical data would suffice in the interest of convenience. In relation to this limitation, there is a possible concern that we deliberately excluded laboratory or spirometric tests, although certain abnormalities have been associated with PPCs. We did so because such tests (notably spirometry) would be difficult to undertake systematically in all clinical settings. In the example of spirometry, most of the patients this test would identify as high risk can be found preoperatively equally well by clinical evaluation of symptoms, 23 which are readily evaluated with the Medical Research Council respiratory questionnaire²⁴ we used.

Possible Usefulness of the Score

We sought a clinically convenient, as well as statistically defensible, scoring system. The American Society of Anesthesiologists physical status classification is a patient-related factor that is consistently reported to be associated with PPCs.² We decided *a priori* to exclude it from the model so as not to mask other factors; furthermore, great variability in an American Society of Anesthesiologists physical status assessment has been reported,²⁸ and we considered it preferable to include objective factors that might be more easily and confidently assessed by clinicians. In this regard, three of the variables included in the risk index we propose (SpO₂, age, and hemoglobin concentration) are easily quantifiable and verifiable, and the three surgical risk factors can be anticipated. In some cases, the risk index may guide strategies to avoid or allay possible PPCs and to prompt the consideration of nonsurgical alternatives or the advisability of postponing surgery for some time. In selected high-risk patients, the preoperative quantification of surgical risk may be of help in explaining risk objectively to patients before scheduling and in encouraging adherence to measures to reduce risk for PPCs, such as preoperative respiratory physiotherapy, among others.²⁹

Given the conspicuous importance of the duration of surgery and the location of the surgical incision in the development of PPCs, special attention should be given to modifying procedures, whenever possible, to shorten them and take tissue-sparing approaches.

In summary, our study identified seven straightforward, objective, and easily assessed factors associated with the appearance of PPCs. A simple risk score based on these factors predicted the development of PPCs in a broad and diverse surgical population sample and allowed us to stratify that sample by level of risk. To test the clinical value of the risk index, we propose to validate it in other geographic areas. Research could also consider the predictive power of preoperative SpO₂ and the advisability of postponing surgery if a

recent respiratory infection is reported, as well as test the effect of treating preoperative anemia.

The authors thank Joan Garcia, M.Inf. (Dinamic Computer, Malgrat de Mar, Barcelona, Spain), for his technical assistance on the research group's website, and Mary Ellen Kerans, M.A. (Freelance Editor, Barcelona, Spain), who revised the English usage in some versions of the manuscript.

References

- Smetana GW: Preoperative pulmonary evaluation. N Engl J Med 1999; 340:937-44
- Smetana GW, Lawrence VA, Cornell JE, American College of Physicians: Preoperative pulmonary risk stratification for noncardiothoracic surgery: Systematic review for the American College of Physicians. Ann Intern Med 2006; 144:581-95
- Fisher BW, Majumdar SR, McAlister FA: Predicting pulmonary complications after nonthoracic surgery: A systematic review of blinded studies. Am J Med 2002; 112:219-25
- Arozullah AM, Khuri SF, Henderson WG, Daley J, Participants in the National Veterans Affairs Surgical Quality Improvement Program: Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major noncardiac surgery. Ann Intern Med 2001; 135:847-57
- Arozullah AM, Daley J, Henderson WG, Khuri SF: Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. The National Veterans Administration Surgical Quality Improvement Program. Ann Surg 2000; 232:242-53
- Sabaté S, Canet J, Muñoz S, Castillo J, Lucas M, Mayoral V: [Epidemiology of anesthesia in catalonia, Spain, in 2003]. Med Clin (Barc) 2006; 126(suppl 2):13-8
- Sabaté S, Canet J, Gomar C, Castillo J, Villalonga A, Investigateurs ANESCAT: [Cross-sectional survey of anaesthetic practices in Catalonia, Spain]. Ann Fr Anesth Reanim 2008; 27:371-83
- Clergue F, Auroy Y, Péquignot F, Jougla E, Lienhart A, Laxenaire MC: French survey of anesthesia in 1996. Anes-THESIOLOGY 1999; 91:1509-20
- Mitchell CK, Smoger SH, Pfeifer MP, Vogel RL, Pandit MK, Donnelly PJ, Garrison RN, Rothschild MA: Multivariate analysis of factors associated with postoperative pulmonary complications following general elective surgery. Arch Surg 1998; 133:194-8
- McAlister FA, Bertsch K, Man J, Bradley J, Jacka M: Incidence of and risk factors for pulmonary complications after nonthoracic surgery. Am J Respir Crit Care Med 2005; 171:514-7
- 11. Maskell NA, Butland RJ, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society: BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 2003; 58(suppl 2):ii8-17
- Duggan M, Kavanagh BP: Pulmonary atelectasis: A pathogenic perioperative entity. Anesthesiology 2005; 102: 838-54
- 13. Brooks-Brunn JA: Postoperative atelectasis and pneumonia. Heart Lung 1995; 24:94-115
- Henry M, Arnold T, Harvey J, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society: BTS guidelines for the management of spontaneous pneumothorax. Thorax 2003; 58(suppl 2):ii39-52
- 15. Marik PE: Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001; 344:665-71
- Liu H, Hussain F, Tan CL, Dash M: Discretization: An enabling technique. Data Min Knowl Discov 2002; 6:393– 423
- 17. Holt NF, Silverman DG: Modeling perioperative risk: Can

- numbers speak louder than words? Anesthesiol Clin 2006; 24:427-59
- Tait AR, Malviya S: Anesthesia for the child with an upper respiratory tract infection: Still a dilemma? Anesth Analg 2005; 100:59-65
- Tait AR, Malviya S, Voepel-Lewis T, Munro HM, Seiwert M, Pandit UA: Risk factors for perioperative adverse respiratory events in children with upper respiratory tract infections. Anesthesiology 2001; 95:299-306
- Mizgerd JP: Acute lower respiratory tract infection. N Engl J Med 2008; 358:716-27
- Brooks-Brunn JA: Predictors of postoperative pulmonary complications following abdominal surgery. Chest 1997; 111:564-71
- Beattie WS, Karkouti K, Wijeysundera DN, Tait G: Risk associated with preoperative anemia in noncardiac surgery: A single-center cohort study. Anesthesiology 2009; 110:574-81
- Sutherland ER, Cherniack RM: Management of chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2689-97
- Medical Research Council Committee on the Aetiology of Chronic Bronchitis. Standardised questionnaire on respiratory symptoms. BMJ 1960; 2:1665-6
- 25. van Schayck CP, van Weel C, Harbers HJ, van Herwaarden CL: Do physical signs reflect the degree of airflow obstruction in patients with asthma or chronic obstructive pulmonary disease? Scand J Prim Health Care 1991; 9:232-8
- 26. Straus SE, McAlister FA, Sackett DL, Deeks JJ: The accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease. CARE-COAD1 Group. Clinical Assessment of the Reliability of the Examination-Chronic Obstructive Airways Disease. JAMA 2000; 283:1853-7
- Noordzij PG, Poldermans D, Schouten O, Bax JJ, Schreiner FA, Boersma E: Postoperative mortality in The Netherlands: A population-based analysis of surgery-specific risk in adults. Anesthesiology 2010; 112:1105-15
- Castillo J, Canet J, Gomar C, Hervás C: [Imprecise status allocation by users of the American Society of Anesthesiologists classification system: Survey of Catalan anesthesiologists]. Rev Esp Anestesiol Reanim 2007; 54:394-8
- 29. Qaseem A, Snow V, Fitterman N, Hornbake ER, Lawrence VA, Smetana GW, Weiss K, Owens DK, Aronson M, Barry P, Casey DE Jr, Cross JT Jr, Fitterman N, Sherif KD, Weiss KB, Clinical Efficacy Assessment Subcommittee of the American College of Physicians: Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery: A guideline from the American College of Physicians. Ann Intern Med 2006; 144:575-80

Appendix. The Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) Group Investigators (listed alphabetically)

Althaia Xarxa Assistencial Manresa: Carme Font, M.D., Meritxell Sabrià, M.D., Anna Font, R.N., Encarna Subirana, R.N., Carme Jándula, R.N., Albert Canadell, M.D., Pere Esquius, M.D.; CIMA (Centro Internacional Medicina Avanzada): Irene Rosell, M.D.; Clínica de Vic: Lourdes Abellán, M.D.; Clínica Plató Fundació Privada: Julio Meza, M.D., Sergi Viedma, M.D., Jordi Guitart, M.D.; Clínica Quirúrgica Onyar (C.M.D., Girona): Roberto Climent, M.D.; Clinica Salus Infirmorum de Banyoles: Luis Eugenio Sarmiento, M.D., Lluís Oduber, M.D.; Espitau Val d'Aran: Horacio Agustín Pena, M.D., Mirtza Gutiérrez, M.D.; FIATC: Francisco Cedo, M.D., Carme Colls, M.D.; Fundació de Gestió Sanitària de l'Hospital de la Santa Creu: Victòria Moral, M.D., Juan

Manuel Campos, M.D., Ana González, M.D., Alfredo Merten, M.D., José Antonio Fernández, M.D., Lucía Hernández, M.D., Mar González, M.D., Adrià Font, M.D.; Fundació Hospital-Asil de Granollers: Núria Isach, M.D., Teresa Vilalta, M.D., Victor Espiga, M.D., Gracia Càrdenas, M.D., Mercè Prieto, M.D.; Fundació Privada Hospital de Mollet: Farid Hobeich, M.D., Joaquim Hernàndez, M.D., Xavier Fargas, M.D.; Hospital Sant Bernabé de Berga: Anna Vidal, M.D., Josep Canudas, M.D.; Fundació Puigvert (IUNA): Pilar Sierra, M.D., Ana Arnal, M.D., Pilar Baxarias, M.D.; Fundació Salut Empordà: Pere Casanovas, M.D., Guillermo Alcibiades Peña, M.D., Manuel Roig, M.D.; Fundació Sanitària d'Igualada: Josep Genís, M.D., Josep M Bausili, M.D.; Hospital Clínic i Provincial de Barcelona: Irene Rovira, M.D., Amalia Alcón, M.D., Teresa Anglada, M.D., Anna López, M.D., José Carretero, M.D., Roger Pujol, M.D., Antonio Ojeda, M.D.; Hospital Clínico Universitario de Valencia: M. Teresa Ballester, M.D., Julio Lloréns, M.D., Francisco Javier Belda, M.D., Miguel Ángel Gil, M.D.; Hospital Comarcal de Blanes: Montserrat Raventós, M.D.; Hospital Comarcal de l'Alt Penedés: Enric Turón, M.D., Teresa Aberasturi, M.D.; Hospital Comarcal de Sant Boi de Llobregat: Ariadna Tuya, M.D., Javier Martínez, M.D.; Hospital Comarcal del Pallars: Antoni Vila, M.D., Xavier Bosch, M.D.; Hospital Comarcal del Ripollès (Hospital de Campdevànol): Ricard Masià, M.D., Sonia Mateo, M.D.; Hospital Comarcal Móra d'Ebre: Robert Masip, M.D., Carles Montoy, M.D.; Hospital de Calella: Enric Manubens, M.D., Cesar Jaramillo, M.D.; Hospital de Girona Dr. Josep Trueta: Antonio Villalonga, M.D., Berta Pardina, M.D., Anna Costa, M.D., José Salvador Sánchez, M.D., Olga Pineda, M.D., Carmen Hernández, M.D.; Hospital de l'Hospitalet: Montserrat Bayo, M.D., Joan Coma, M.D., Lydia Buisan, M.D.; Hospital de Mataró: Isabel Cabré, M.D., Lluïsa Opisso, M.D., Yolanda Jiménez, M.D., Nerea Sanchís, M.D.; Hospital de Puigcerdà (Centre Hospitalari de la Cerdanya): A Tomás Esteban, M.D., Manel Jiménez, M.D.; Hospital de Sabadell: Carmen Colilles, M.D., Nuria Guilera, M.D., Elisabeth Hansen, M.D., Carmen Díaz, M.D., Jordi Torrellardona, M.D., Dolors Molies, M.D.; Hospital de Sant Celoni Fundació Privada: Rosa M. Tarradell, M.D., Anna Serra, M.D.; Hospital de Sant Pau i Santa Tecla de Tarragona: Raúl Benlloch, M.D., M. Pilar Roca, M.D., Nestor Jarma, M.D.; Hospital de Terrassa: Carmen Martín, M.D., Pilar Moragriega, M.D., Giacomo Ledda, M.D.; Hospital de Viladecans: M.José Linares, M.D., Elisenda Izquierdo, M.D., Francisco Nebot, M.D.; Hospital del Vendrell: Antonio Chamero, M.D., M. José Sanchez, M.D.; Hospital Dos de Maig (Consorci Sanitari Integral): Josep Masdeu, M.D., José Antonio Villanueva, M.D., José Miguel Moncho, M.D., Hospital Fundación Mossen Costa (Palamós): Héctor Oreiro, M.D., Rodrigo Galán, M.D., Onel Morales, M.D., Hospital General de Catalunya: Julián Roldán, M.D., Pilar Santos, M.D., Demetrio Mulas, M.D., Elena Hernando, M.D.; Hospital General de Vic: Teresa Planella, M.D., Jordi Serrat, M.D., Silvia Cardoner, M.D.; Hospital Mar-Esperança (IMAS): Lluís Aguilera, M.D., Xavier Santiveri, M.D., Fernando Escolano, M.D., Rosario Armand-Ugon, M.D., Lucía Valencia, M.D., Mónica Williams, M.D., Amelia Rojo, M.D.; Hospital Municipal de Badalona: M. Dolors Sintes, M.D., Lluis Martinez, M.D., Fernando Rey, M.D.; Hospital Mútua de Terrassa: Jesús Antonio Martínez, M.D., Francisco Eugenio Fontao, M.D., Mónica Pérez, M.D., Juan Ortega, M.D., Marta Lopez, M.D., José Bernal, M.D., Carme Pérez, M.D.; Hospital Sant Jaume d'Olot: Josep M Corominas, M.D., Patricia Conde, M.D., Carlos Castro, M.D.; Hospital Sant Joan de Déu de Martorell: Lluís Muñoz, M.D., Albert Codina, M.D., Rosa Urday,

M.D.; Hospital Santa Caterina: Benet Casagran, M.D., Julio César Paredes, M.D.; Hospital Santa María de Lleida: Montserrat Torra, M.D., Rosa M. Urgell, M.D., M. Paz Villalba, M.D., M. Dolors del Pozo, M.D.; Hospital Universitari Arnau de Vilanova de Lleida: Tomás Martínez, M.D., José Luis Gómez, M.D., Rafael González, M.D., Herminio Obón, M.D.; Hospital Universitari de Bellvitge: Antonio Montero, M.D., Lucía García Huete, M.D., Eva Digón, M.D., Ana Cabrera, M.D., Teresa Alcázar, M.D., Víctor Mayoral, M.D., Ana Belén Pedregosa, M.D., Roser Torruella, M.D., Federico Gregorio Carol, M.D.; Hospital Universitari de Sant Joan de Reus: Jesús Cuenca, M.D., Pilar Prieto, M.D., Susana Bella, M.D.; Hospital Universitari de Tarragona Joan XXIII (Universitat Rovira i Virgili): María Rull, M.D., Benjamín Solsona, M.D., Ione Mon-

talvo, M.D., Silvia Coves, M.D., Barbara Méndez, M.D.; Hospital Universitari Germans Trias i Pujol: M. Teresa Sariñena, M.D., Mónica Rodríguez, M.D., Esther Vilà, M.D., Agnès Martí, M.D., Alfonso Rengel, M.D., Susana Muñoz, M.D.; Hospital Universitari Sagrat Cor: Vicente De Sanctis, M.D., Isabel Arias, M.D., Manuel Mateo, M.D.; Hospital Universitari Vall d'Hebron: Jaume Roigé, M.D., Rosa Sala, M.D., Patricia Bascuñana, M.D., Anna Rodriguez, M.D., Elena Serrano, M.D., Montserrat Ribas, M.D., Pilar Cortiella, M.D., Javier Medel, M.D., Esther Márquez, M.D., Inmaculada Salgado, M.D.; Hospital Verge de la Cinta de Tortosa: Carmelo Lozano, M.D., Antoni Serrat, M.D.; MC Mutual: Carlos Morros, M.D., M., Dolores Pérez, M.D.; Pius Hospital de Valls: Josep M Serra, M.D., Juan Pablo Lorenzo, M.D.

ANESTHESIOLOGY REFLECTIONS

Erdmann's Life Membership No. 1 in the ASA



In 1905 Adolph Frederick Erdmann, M.D. (1867–1953), gathered eight medical colleagues and founded the Long Island Society of Anesthetists, a group which evolved successively into the New York Society of Anesthetists (1911), the American Society of Anesthetists (1935), and finally the American Society of Anesthesiologists (ASA) (1945). A teetotaling nonsmoker, Erdmann invented an ether dropper and promoted use of perioperative music for relaxing patients. After "Fred" Erdmann retired in 1937 from active practice, the Society's secretary, Paul M. Wood, M.D., signed a wallet-sized "Silver Certificate" (above) that declared that Erdmann was "a member in good standing for the year life" and "Active Member No. 1." In 1947 the ASA honored Erdmann with its third Distinguished Service Award. (Copyright © the American Society of Anesthesiologists, Inc. This image appears in color in the Anesthesiology Reflections online collection available at www.anesthesiology.org.)

George S. Bause, M.D., M.P.H., Honorary Curator, ASA's Wood Library-Museum of Anesthesiology, Park Ridge, Illinois, and Clinical Associate Professor, Case Western Reserve University, Cleveland, Ohio. UJYC@aol.com.